Silexion Therapeutics (SLXN) vs VivoSim Labs (VIVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Silexion Therapeutics is the larger company by market cap ($3.1 million vs $3.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLXN | VIVS |
|---|---|---|
| Share price | $0.2146 | $0.1801 |
| Market cap | $3.11M | $2.99M |
| 1-day change | -8.64% | +1.64% |
| EPS (TTM) | $-27.21 | $-4.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.40 | $3.40 |
| 52-week low | $0.2079 | $0.1681 |
| Distance from 52-week high | -99.46% | -94.70% |
| Analyst consensus | none | — |
| Avg. price target upside | +2229.92% | — |
| Average volume | 10.05M | 5.93M |
| Shares outstanding | 14.47M | 16.59M |
| Employees | 13 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Silexion Therapeutics
SLXN stock →Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 13 employees
About VivoSim Labs
VIVS stock →VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
SLXN vs VIVS FAQ
Which is bigger, Silexion Therapeutics or VivoSim Labs?
Silexion Therapeutics (SLXN) is larger, with a market capitalization of $3.11M compared with $2.99M for VivoSim Labs (VIVS).
Are Silexion Therapeutics and VivoSim Labs in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.